Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine

Esther Redondo, Georgina Drago, Juan Luis López-Belmonte, Jose María Guillén, Helene Bricout, Fabián P. Alvarez, Daniel Callejo, Ángel Gil de Miguel
2021 Vaccine  
The normal ageing process is accompanied by immunosenescence and a progressive weakening of the immune system. High-dose inactivated influenza quadrivalent vaccine (HD-QIV) has shown greater immunogenicity, relative efficacy, and effectiveness than the standard-dose inactivated quadrivalent vaccine (SD-QIV). The aim of the study was to assess the cost-utility of an HD-QIV strategy compared with an adjuvanted trivalent inactivated vaccine (aTIV) strategy in the population above 65 years of age in Spain.
doi:10.1016/j.vaccine.2021.07.048 pmid:34344553 fatcat:7q4dbzplzvdstifif4kkiqw77e